Balaxi Pharmaceuticals Ltd

At Rs 28.41, sellers were still queuing — but there were no buyers willing to take the other side. Balaxi Pharmaceuticals Ltd locked at its lower circuit of 5% on 11 May 2026, with unfilled sell orders and a frozen price.

Balaxi Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

At Rs 28.88, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Balaxi Pharmaceuticals Ltd locked at its upper circuit of 3.6% on 7 May 2026, with buyers queuing and no sellers willing to part with shares.

Balaxi Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 April 2026, providing investors with the latest insights into its performance and outlook.

At Rs 28.00, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Balaxi Pharmaceuticals Ltd locked at its upper circuit of 4.99% on 21 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Balaxi Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 April 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Balaxi Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 April 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

At Rs 18.80, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Balaxi Pharmaceuticals Ltd locked at its upper circuit of 19.97% on 1 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 27 March 2026, providing investors with the latest perspective on the company’s position.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 15 March 2026, providing investors with the latest insights into the stock’s performance and outlook.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 03 March 2026, providing investors with the latest insights into its performance and outlook.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 20 February 2026, providing investors with the latest perspective on the stock’s performance and prospects.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 09 February 2026, providing investors with an up-to-date view of its performance and outlook.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 29 January 2026, providing investors with the latest data to inform their decisions.

Balaxi Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended December 2025, marking a notable shift from its previous negative trend. Despite the absence of key negative triggers, the company continues to face significant headwinds, reflected in its long-term stock underperformance relative to the broader market.

Balaxi Pharmaceuticals Ltd. reported a devastating 94.22% year-on-year decline in net profit for Q3 FY26, with earnings collapsing to just ₹0.31 crores from ₹5.36 crores in the same quarter last year. The micro-cap pharmaceutical company, with a market capitalisation of ₹137.00 crores, saw its profit margins evaporate to a mere 0.43%, down from 7.31% in Q3 FY25, as an extraordinary tax burden and operational inefficiencies ravaged the bottom line. The stock, trading at ₹25.14, has plunged 62.72% over the past year, underperforming the pharmaceutical sector by a staggering 86.83 percentage points.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market trends.